Application of lotus leaf crude polysaccharide in prevention and treatment of ulcerative enteritis and salpingitis

The crude polysaccharide of lotus leaf is extracted by water alcohol extraction method, and its antioxidant, anti-inflammatory and regulating intestinal flora are studied, which solves the treatment problems of ulcerative enteritis and fallopian tubes in livestock and poultry, and achieves the ulcerative enteritis and fallopian tubes. Effective prevention and treatment of inflammation have increased egg laying rate.

CN119055676APending Publication Date: 2024-12-03YUNNAN AGRICULTURAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410943260.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat ulcerative enteritis and fallopian tuberitis in livestock and poultry, resulting in a decrease in egg laying rate and economic losses.

Method used

The crude polysaccharide of lotus leaf was extracted by water alcohol extraction method, and the effects of antioxidant, anti-inflammatory and regulating intestinal flora were studied through UC mouse model and bacterial fallopianitis model, and explored its in ulcerative enteritis and fallopianitis in ulcerative enteritis and fallopianitis. therapeutic potential.

Benefits of technology

The crude polysaccharide of lotus leaves significantly reduces the release of inflammatory factors, restores intestinal barrier function, regulates intestinal flora balance, improves egg laying rate, and effectively prevents and treats ulcerative enteritis and fallopian tubeitis, providing new drug targets.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055676A_ABST
    Figure CN119055676A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of natural product extraction and medicine, and particularly relates to application of lotus leaf crude polysaccharide in prevention and treatment of ulcerative enteritis and salpingitis. Lotus leaves are used as a raw material, a water extraction and alcohol precipitation method is adopted to obtain the lotus leaf crude polysaccharide, and in-vitro experiments prove that the lotus leaf crude polysaccharide is a polysaccharide with antioxidant and anti-inflammatory effects and is an ideal polysaccharide for preventing and treating ulcerative enteritis. In a DSS-induced ulcerative enteritis mouse model, by giving the lotus leaf crude polysaccharide, the mouse colitis symptom can be effectively relieved, the barrier function of colon is recovered, the inflammatory factor level is reduced, and the intestinal flora balance of the mouse is regulated. In a laying hen salpingitis model induced by mixed bacterial infection, the inflammation symptom of the salpingitis laying hen salpingitis can be effectively relieved by giving the lotus leaf crude polysaccharide, the physiological function of the salpingitis laying hen is recovered, and the laying rate is increased. Meanwhile, according to the technical scheme, the extraction and preparation method is simple, industrial implementation is facilitated, and therefore good economic and social benefits can be obtained.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product extraction and medicine, and particularly relates to application of crude lotus leaf polysaccharide in the prevention and treatment of ulcerative enteritis and salpingitis. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Enteritis is a common disease in the livestock and poultry industry and pet clinics, and can be divided into infectious and non-infectious types. Infectious enteritis is usually caused by specific pathogenic microorganisms, such as chicken bursal disease, porcine epidemic diarrhea, canine parvovirus disease, and Escherichia coli enteritis, with vomiting, diarrhea, watery stools, bloody stools, and feces mixed with mucus as the main characteristics; non-infectious enteritis is affected by environmental, dietary, immune and other factors. Sick livestock and poultry show symptoms such as diarrhea and slow growth, which seriously affects the development of animal husbandry and human health. Especially in poultry farming, because poultry is a bird, the oviduct is also present in the abdominal cavity and is close to the intestine. After the pathogen enters the intestine, it can infect the oviduct and cause oviduct inflammation. Salpingitis can easily break out on a large scale in laying hen farms, causing a decrease in egg production and the death of laying hens. It can reduce egg production by 5% to 30% and increase mortality by 10% to 25%, posing a threat to egg production and global food security, causing huge economic losses and hindering the sustainable development of large-scale laying hen farming.

[0004] Lotus leaf, the dried leaf of the lotus plant of the Nymphaeaceae family, has been used as a food additive for more than 2,000 years, especially as herbal tea for health care and traditional Chinese medicine treatment. It has been included in the "medicine and food homology" catalog by the National Health Commission of China. Traditional medicine believes that lotus leaf is cold in nature and belongs to the liver, spleen and stomach meridians. It has the effects of relieving summer heat and clearing away heat, generating and clearing yang, and dispersing blood stasis and stopping bleeding. "Compendium of Materia Medica" records that it is often used for: generating vitality, helping the spleen and stomach, astringing turbid semen, dispersing blood stasis, clearing edema, carbuncle, and acne. Modern pharmacological studies have shown that lotus leaf has a variety of therapeutic effects, including anti-hyperlipidemia, anti-diabetes, anti-obesity, antioxidant, anti-inflammatory, anti-atherosclerosis, anti-cancer, and liver protection. Lotus leaf has a wide range of pharmacological effects, which is closely related to its rich and diverse bioactive ingredients. So far, the bioactive ingredients found in lotus leaves include alkaloids, polysaccharides, flavonoids, lignans, amino acids and minerals.

[0005] Polysaccharides are considered to be the most abundant component in lotus leaf tea beverages, accounting for about 3.22% to 6.31% (w / w). Polysaccharides are macromolecules with biological activity. Studies have shown that polysaccharides can effectively prevent and improve colon damage and immune system disorders caused by inflammatory bowel disease (IBD). The main mechanism of action is to reduce neutrophil infiltration during inflammation, inhibit oxidative stress and lipid peroxidation, protect the antioxidant system, inhibit proinflammatory cytokines, or regulate intestinal microorganisms and their metabolites to prevent and treat IBD. It can also promote intestinal mucosal adhesion, enhance targeting of specific tissues and reduce inflammatory responses by regulating intestinal microorganisms, and has a significant intervention effect on IBD. However, there are few reports on the treatment of inflammatory bowel disease with lotus leaf polysaccharides. Summary of the invention

[0006] In view of the deficiencies of the prior art, the present invention provides the application of crude polysaccharides from lotus leaves in the prevention and treatment of ulcerative enteritis and salpingitis. Specifically, the present invention extracts crude polysaccharides from lotus leaves by water extraction and alcohol precipitation, conducts in vivo and in vitro anti-inflammatory experiments, and establishes a UC mouse model to study the effects of crude polysaccharides from lotus leaves on the intestinal barrier and intestinal flora caused by UC, and further analyzes its efficacy description through microbiology and metabolomics; at the same time, a bacterial salpingitis model is established to study the effects of lotus leaf polysaccharides on the decreased egg production rate and oviduct tissue lesions caused by salpingitis in laying hens, and to find new targets for the drug treatment of inflammatory diseases in livestock and poultry. Based on the above research results, the present invention is completed.

[0007] In order to achieve the above technical objectives, the technical solution adopted by the present invention is as follows:

[0008] The first aspect of the present invention provides the use of crude lotus leaf polysaccharide in any one or more of the following:

[0009] (a) Anti-oxidation or preparation of anti-oxidation products;

[0010] (b) Anti-inflammatory or preparation of anti-inflammatory products;

[0011] (c) regulating intestinal flora disorders or preparing products for regulating intestinal flora disorders.

[0012] Among them, in said (a), the antioxidant capacity is specifically manifested as the improvement and / or enhancement of DPPH scavenging rate, ABTS scavenging capacity and T-AOC total antioxidant capacity.

[0013] In said (b), said anti-inflammatory activity is specifically manifested as in vitro anti-inflammatory activity and in vivo anti-inflammatory activity;

[0014] Among them, the in vitro anti-inflammatory ability is manifested in that lotus leaf polysaccharide improves LPS-mediated oxidative stress response and inflammatory factor release.

[0015] Specifically, lotus leaf crude polysaccharides enhanced the activities of SOD and GSH induced by LPS, reduced the activities of LDH and CAT, and inhibited the release of inflammatory factors such as NO, TNF-α, IL-6, IL-1β, and IL-10.

[0016] The anti-inflammatory ability in vivo is specifically manifested in the prevention and / or treatment of inflammatory diseases;

[0017] Wherein, the inflammatory diseases at least include ulcerative enteritis and salpingitis.

[0018] According to the present invention, the concept of "prevention and / or treatment" refers to any measure applicable to the treatment of ulcerative enteritis, salpingitis and other related diseases, or preventive treatment of such diseases or symptoms, or avoidance of recurrence of such diseases, such as recurrence after the end of the treatment period or treatment of symptoms of the disease that has already occurred, or pre-interventional prevention, inhibition or reduction of the occurrence of such diseases or symptoms.

[0019] Prevention and / or treatment of ulcerative enteritis at least includes: reduction in weight loss of subjects, reduction in DAI score, restoration of intestinal mucosal damage, reduction in inflammatory cell infiltration, and reduction in inflammation level;

[0020] Prevention and / or treatment of fallopian tube inflammation at least includes: increasing egg production, relieving fallopian tube inflammation symptoms, and restoring the physiological function of the fallopian tube.

[0021] In the above (c), regulating the intestinal flora disorder is specifically manifested as: reversing the intestinal microbial flora disorder caused by DSS, specifically at least increasing the abundance of Firmicutes and reducing the abundance of Bacteroidetes.

[0022] In a specific embodiment of the present invention, the ulcerative enteritis is induced by DSS; the salpingitis is induced by pathogenic bacteria (such as Escherichia coli and Staphylococcus aureus).

[0023] The user of the product can be a human or a non-human animal, wherein the non-human animal can be a mammal or a bird, in particular, a livestock animal, such as a pig, a cow, a sheep, a horse, a donkey, a mule, a rabbit, a chicken, a duck, a goose, a pigeon, etc. In addition, non-human animals raised as pets, in particular mammals (such as cats, dogs, etc.) and birds (such as parrots, canaries, thrushes, etc.), are also within the scope of protection of the present application.

[0024] The product can be a medicine or a food. When the product is administered to a non-human animal, the medicine is a veterinary drug, and the food can be a feed additive (or a pet food additive). Obviously, it can be used as a functional food.

[0025] The crude lotus leaf polysaccharide in the present invention is a polysaccharide component extracted from lotus leaves. Specifically, the crude lotus leaf polysaccharide is prepared by a water extraction and alcohol precipitation method.

[0026] The second aspect of the present invention provides a method for preparing crude lotus leaf polysaccharide, the preparation method comprising:

[0027] (1) extracting lotus leaves through alcohol to remove fat-soluble small molecules and pigments, thereby obtaining lotus leaf residues;

[0028] (2) drying the lotus leaf residue obtained in step (1), adding water and heating it for extraction, filtering it and collecting the filtrate;

[0029] (3) subjecting the filtrate obtained in step (2) to alcohol precipitation and collecting the precipitate;

[0030] (4) After removing the protein from the precipitate in step (3), crude lotus leaf polysaccharide is obtained.

[0031] In a specific embodiment of the present invention, the yield of crude lotus leaf polysaccharide is 3.408%.

[0032] In the step (1), the specific method of alcohol extraction comprises: crushing the lotus leaves and treating them with high concentration ethanol (such as 95% ethanol) at 70-90° C. (preferably 80° C.) under reduced pressure reflux for 2-4 times (preferably 2 times), each time for 1-3 hours (preferably 2 hours); the mass volume ratio of the lotus leaves to the ethanol is 1:3-10, g / mL (preferably 1:6, g / mL);

[0033] In the step (2), the drying can be natural drying in the shade, and the specific conditions for water heating extraction include: the extraction temperature is controlled at 90-100°C (preferably 95°C), the extraction time is 1-3 hours (preferably 2 hours), the number of extractions is 1-3 times (preferably 2 times), and the mass volume ratio of the dried medicinal residue to water is 1:5-12, g / mL (preferably 1:8, g / mL).

[0034] In the step (3), the alcohol precipitation treatment method comprises: adding 90% ethanol to the filtrate to make the final concentration 80%, precipitating the polysaccharide with alcohol, and collecting the precipitate after standing; the standing treatment time is 10-40 hours (preferably 24 hours).

[0035] In the step (4), the protein is removed by the Sevage method; the specific method comprises: adding water to the precipitate to obtain an aqueous solution, wherein the mass volume ratio of the precipitate to the water is 1:5-15, preferably 1:10 (g / mL); then mixing the aqueous solution containing the precipitate with the Sevage solution in a volume ratio of 2-6:1 (preferably 4:1) to remove the protein; further, using a 3.5KDa dialysis bag in flowing water for 48 hours to remove the organic reagent to obtain a crude polysaccharide solution; and freeze-drying the crude polysaccharide solution to obtain lotus leaf crude polysaccharide.

[0036] The third aspect of the present invention provides a product, which at least contains the above-mentioned lotus leaf crude polysaccharide.

[0037] The product can be a medicine or a food. When the product is administered to a non-human animal, the medicine is a veterinary drug, and the food can be a feed additive (or a pet food additive). Obviously, it can be used as a functional food.

[0038] The product has any one or more of the following uses:

[0039] (a) Antioxidant;

[0040] (b) anti-inflammatory;

[0041] (c) Regulate intestinal flora disorders.

[0042] Among them, in said (a), the antioxidant capacity is specifically manifested as the improvement and / or enhancement of DPPH scavenging rate, ABTS scavenging capacity and T-AOC total antioxidant capacity.

[0043] In said (b), said anti-inflammatory activity is specifically manifested as in vitro anti-inflammatory activity and in vivo anti-inflammatory activity;

[0044] Among them, the in vitro anti-inflammatory ability is manifested in that lotus leaf polysaccharide improves LPS-mediated oxidative stress response and inflammatory factor release.

[0045] Specifically, lotus leaf crude polysaccharides enhanced the activities of SOD and GSH induced by LPS, reduced the activities of LDH and CAT, and inhibited the release of inflammatory factors such as NO, TNF-α, IL-6, IL-1β, and IL-10.

[0046] The anti-inflammatory ability in vivo is specifically manifested in the prevention and / or treatment of inflammatory diseases;

[0047] Wherein, the inflammatory diseases at least include ulcerative enteritis and salpingitis.

[0048] According to the present invention, the concept of "prevention and / or treatment" refers to any measure applicable to the treatment of ulcerative enteritis, salpingitis and other related diseases, or preventive treatment of such diseases or symptoms, or avoidance of recurrence of such diseases, such as recurrence after the end of the treatment period or treatment of symptoms of the disease that has already occurred, or pre-interventional prevention, inhibition or reduction of the occurrence of such diseases or symptoms.

[0049] Prevention and / or treatment of ulcerative enteritis at least includes: reduction in weight loss of subjects, reduction in DAI score, restoration of intestinal mucosal damage, reduction in inflammatory cell infiltration, and reduction in inflammation level;

[0050] Prevention and / or treatment of fallopian tube inflammation at least includes: increasing egg production, relieving fallopian tube inflammation symptoms, and restoring the physiological function of the fallopian tube.

[0051] In the above (c), regulating the intestinal flora disorder is specifically manifested as: reversing the intestinal microbial flora disorder caused by DSS, specifically at least increasing the abundance of Firmicutes and reducing the abundance of Bacteroidetes.

[0052] In a specific embodiment of the present invention, the ulcerative enteritis is induced by DSS; the salpingitis is induced by pathogenic bacteria (such as Escherichia coli and Staphylococcus aureus).

[0053] The user of the product can be a human or a non-human animal, wherein the non-human animal can be a mammal or a bird, in particular, a livestock animal, such as a pig, a cow, a sheep, a horse, a donkey, a mule, a rabbit, a chicken, a duck, a goose, a pigeon, etc. In addition, non-human animals raised as pets, in particular mammals (such as cats, dogs, etc.) and birds (such as parrots, canaries, thrushes, etc.), are also within the scope of protection of the present application.

[0054] Beneficial technical effects of one or more of the above technical solutions:

[0055] In the above technical scheme, lotus leaf is used as raw material, and lotus leaf crude polysaccharide is obtained by water extraction and alcohol precipitation. In vitro experiments have proved for the first time that lotus leaf crude polysaccharide (LLP) is a polysaccharide with antioxidant and anti-inflammatory effects. It is an ideal polysaccharide for the prevention and treatment of ulcerative colitis and can be developed as a functional food or candidate drug. In the DSS-induced ulcerative colitis mouse model, administration of lotus leaf crude polysaccharide can effectively alleviate the symptoms of colitis in UC mice, restore the barrier function of the colon, reduce the level of inflammatory factors and regulate the balance of intestinal flora in UC mice. In the laying hen salpingitis model induced by mixed bacterial infection, administration of lotus leaf crude polysaccharide can effectively alleviate the inflammatory symptoms of the oviduct of laying hens with salpingitis, restore the physiological function of the oviduct, and increase the egg production rate. At the same time, the extraction and preparation method of the above technical scheme is simple and easy to implement in industrialization, so it can achieve good economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0057] Figure 1 The antioxidant activity of the crude lotus leaf polysaccharide in the examples of the present invention, A: DPPH scavenging rate; B: ABTS scavenging ability; C: T-AOC total antioxidant capacity.

[0058] Figure 2 This is the safe concentration of crude lotus leaf polysaccharide in the embodiments of the present invention.

[0059] Figure 3 The inflammatory factor contents of cell supernatant of lotus leaf crude polysaccharide on LPS-induced cell inflammation in the examples of the present invention are: A: NO secretion; B: IL-6 secretion; C: TNF-α secretion; D: IL-10 secretion; E: IL-1β secretion.

[0060] Figure 4 These are the related indicators of the crude lotus leaf polysaccharide on LPS-induced cellular oxidative stress in the examples of the present invention, A: SOD; B: LDH; C: CAT; D: GSH.

[0061] Figure 5 These are the physical sign indicators of the crude lotus leaf polysaccharide on DSS-induced enteritis mice in the examples of the present invention, A: weight change; B: DAI score; C: colon length; D: colon length measurement.

[0062] Figure 6 The colon sections of mice with DSS-induced enteritis induced by crude lotus leaf polysaccharide in the examples of the present invention are shown in A: HE staining (40×, 100×); B: PAS staining (40×, 100×).

[0063] Figure 7 These are the immune organ indexes of the crude lotus leaf polysaccharide on DSS-induced enteritis mice in the examples of the present invention, A: spleen index; B: thymus index.

[0064] Figure 8 This is an immunofluorescence section of the colon of a mouse with DSS-induced enteritis induced by crude lotus leaf polysaccharide in an example of the present invention, A: ZO-1; B: ZO-1 content; C: Occludin; D: Occludin content; E: Claudin-1; F: Claudin-1 content.

[0065] Fig. 9The results are as follows: The effects of crude lotus leaf polysaccharide on the contents of inflammatory factors in the colon tissue homogenate of DSS-induced enteritis mice, A: NO secretion; B: TNF-α secretion; C: IL-1β secretion; D: IL-10 secretion; E: IL-6 secretion.

[0066] Fig.10 The following are the effects of crude lotus leaf polysaccharide on the levels of inflammatory factors in the serum of mice with DSS-induced enteritis: A: NO secretion; B: TNF-α secretion; C: IL-1β secretion; D: IL-10 secretion; E: IL-6 secretion. Fig.11 The data of the effect of lotus leaf crude polysaccharide on the intestinal flora of mice with DSS-induced enteritis in the examples of the present invention are shown in Figure 1. A: α diversity analysis; B: β diversity analysis; C: Venn type; D: PCA analysis.

[0067] Fig.12 The effects of crude lotus leaf polysaccharide on the intestinal flora of mice with DSS-induced enteritis at different levels in the examples of the present invention, A: phylum level; B: family level; C: genus level.

[0068] Fig.13 This is an analysis of the metabolic pathways of microorganisms producing crude lotus leaf polysaccharides in an embodiment of the present invention.

[0069] Fig.14 These are the observation data on the clinical symptoms of the oviduct of laying hens with salpingitis caused by crude lotus leaf polysaccharide in the examples of the present invention.

[0070] Fig.15 The results are as follows: the effect of crude lotus leaf polysaccharide on the number of white blood cells in laying hens with salpingitis in the examples of the present invention.

[0071] Fig.16 This is the observation result (40×) of the pathological section of the oviduct tissue of laying hens with salpingitis by crude lotus leaf polysaccharide in the example of the present invention. DETAILED DESCRIPTION

[0072] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0073] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components and / or combinations thereof. It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the embodiments of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention.

[0074] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0075] Example

[0076] Experimental methods:

[0077] Preparation of Crude Lotus Leaf Polysaccharide

[0078] The lotus leaves were crushed and then treated with 6 times the amount of 95% ethanol (g:mL) at 80°C under reduced pressure and reflux for 2 times, and the fat-soluble small molecules and pigments were removed by alcohol extraction for 2 hours each time to obtain the medicinal residues; the obtained medicinal residues were naturally dried in the shade and then added with 8 times the amount of water (g:mL) for heating and extraction (extraction temperature 95°C, extraction time 2 hours, extraction times twice), and the filtrate was collected after filtration; the obtained filtrate was subjected to alcohol precipitation (90% ethanol was added to the filtrate to make the final concentration 80%, and the polysaccharide was precipitated by alcohol, and the precipitate was collected after standing; The precipitation was allowed to stand for 24 hours, and the precipitate was collected; water was added to the precipitate at a mass volume ratio of 1:10 (g / mL) to obtain an aqueous solution, which was then mixed with a Sevage solution (the mass ratio of chloroform to n-butanol was 4:1) at a volume ratio of 4:1, and the solution was allowed to stand for centrifugation after shaking to obtain an upper polysaccharide solution, and the steps were repeated 7 times until the protein was completely removed; the solution was then dialysis bag with a 3.5KDa in flowing water for 48 hours to remove the organic reagent to obtain a crude polysaccharide solution; the crude polysaccharide solution was freeze-dried to obtain lotus leaf crude polysaccharide.

[0079] Antioxidant activity of crude polysaccharides from lotus leaves

[0080] According to the instructions, the antioxidant capacity of crude lotus leaf polysaccharide was tested by DPPH, ABTS and T-AOC, and the antioxidant capacity of crude lotus leaf polysaccharide was evaluated by the three antioxidant indices.

[0081] DPPH capacity test:

[0082] (1) Reagent preparation: Accurately weigh 0.002 g DPPH and add it to 50 mL distilled water to obtain a 0.1 m mol / L DPPH working solution. Wrap the solution in tin foil and store it away from light. Prepare it freshly each time.

[0083] (2) Operation steps: Take a 96-well plate and add 100 μL of gradient lotus leaf crude polysaccharide solution and 100 μL of DPPH working solution to each well. Incubate at room temperature in the dark for 30 minutes.

[0084] The absorbance of each well was measured at 517 nm. The blank group used anhydrous ethanol instead of DPPH working solution, and the control group used deionized water instead of gradient lotus leaf crude polysaccharide solution.

[0085] The formula is as follows:

[0086]

[0087] In this formula, Ab is the absorbance value of the blank group, Ac is the absorbance value of the control group, and As is the absorbance value of the sample group. ABTS+ free radical scavenging ability:

[0088] (1) Reagent preparation: Accurately weigh 0.0407 g of ABTS diammonium salt into 10 mL of deionized water to obtain 7.4 mmol / L; accurately weigh 0.007 g of K2S2O8 into 100 mL of deionized water to obtain 2.6 mmol / L; mix the prepared ABTS solution and K2S2O8 solution in equal volumes at a ratio of 1:1 and add them to a brown bottle, then wrap it with tin foil, incubate it in the dark for 12 h, and then dilute it with phosphate buffer at pH = 7.4 until the absorbance = 0.7 ± 0.02, which is the ABTS free radical working solution.

[0089] (2) Operation steps: Take a 1.5 mL centrifuge tube, add 200 μl of gradient lotus leaf crude polysaccharide solution, 800 μl of ABTS free radical working solution, mix well, incubate for 6 min under light-proof conditions, take 100 μl from each tube and add it to the enzyme label strip, use an enzyme reader to measure the absorbance at 734 nm, and measure each sample three times in parallel to reduce errors. The blank group uses deionized water instead of the sample solution, and the control group uses deionized water instead of the ABTS free radical working solution.

[0090]

[0091] In this formula, Ab is the absorbance value of the blank group, Ac is the absorbance value of the control group, and As is the absorbance value of the sample group.

[0092] Total antioxidant capacity of T-AOC:

[0093] (1) Reagent preparation: Accurately weigh 1 g potassium ferrocyanide in 100 mL deionized water to obtain 1%; accurately weigh 10 g trichloroacetic acid in 100 mL deionized water to obtain 10%; accurately weigh 1 g ferric chloride in 100 mL deionized water to obtain 1%; accurately weigh 1.74 g sodium dihydrogen phosphate, 2.7 g disodium hydrogen phosphate, and 1.7 g NaCl, and dilute to 400 mL with deionized water to obtain a phosphate buffer solution with a pH of 6.6.

[0094] (2) Operation steps: Take a 15mL centrifuge tube, add 2.5mL of gradient lotus leaf crude polysaccharide solution, 2.5mL of phosphate buffer, 2.5mL of potassium ferricyanide solution, mix well and place in a water bath at 50℃ for 20min. Then add 2.5mL of trichloroacetic acid solution, mix well and centrifuge at 4000rpm / min for 5min. Take a 10mL centrifuge tube, add 2.5mL of supernatant, 2.5mL of deionized water and 0.5mL of ferric chloride solution, mix well and place at room temperature for 10min. Centrifuge at 8000rpm / min for 5min. Collect the supernatant, take 100μL of each tube in the enzyme label strip, and measure the absorbance at 700nm. The blank group used deionized water instead of lotus leaf crude polysaccharide solution, and the control group used deionized water instead of ferric chloride solution.

[0095] Antioxidant and anti-inflammatory effects of crude lotus leaf polysaccharides in vitro

[0096] Cultivation of RAW264.7 cells:

[0097] (1) Cell recovery: Take the frozen RAW264.7 mouse macrophages out of the -80℃ freezer and follow the principle of "quick dissolution" by soaking the cryotubes in a preheated 37℃ water bath to dissolve them within 1 minute. Transfer the thawed RAW264.7 mouse macrophages into the prepared complete culture medium in the clean bench. The complete culture medium consists of 10% serum and 90% DMEM culture medium, and 1% double antibody is added.

[0098] (2) Cell passaging: Observe the cell growth density in the culture flask under a microscope every day. When the density reaches about 90%, the cells can be passaged. The steps for cell passaging are as follows: discard the culture medium in the culture flask and add an appropriate amount of PBS to rinse the flask. RAW264.7 mouse macrophages are immune cells and are relatively sensitive. Therefore, they are not digested with trypsin. Instead, add 2 mL of complete culture medium and use a pipette to gently blow the cells in the flask to blow the cells off the wall of the cell flask. You can observe under a microscope whether the cells have completely fallen off. After they have completely fallen off, use a pipette to blow them again to disperse them into single cells instead of cell clumps. Next, adjust the cell density to 5x10 4100 μg / mL, inoculated into a new culture bottle, and placed in the incubator for further culture. Cells after passage 3 were used for all subsequent experiments.

[0099] Determination of safe concentration of crude polysaccharide from lotus leaf

[0100] A 10 mg / mL lotus leaf crude polysaccharide solution was prepared, filtered with a 0.22 μm filter membrane in a clean bench, and then diluted with DMEM culture medium to the following concentration gradient: 100, 200, 400, 800, 1000 μg / mL.

[0101] Culture RAW264.7 mouse macrophages and collect them after they grow normally to the logarithmic growth phase. Resuspend the cells in complete medium containing serum and adjust the cell density to 1x10 5 , then use a spray gun to add 100μL of cell suspension to each well, evenly spread it on the inside of the 96-well plate, and seal the periphery with an equal amount of PBS. Culture in the incubator for 12 hours, and the next experiment can be carried out after the cells adhere to the wall. Then discard the culture medium in the 96-well cell culture plate and rinse twice with PBS. Add complete culture medium containing different concentrations of lotus leaf crude polysaccharides and culture for 24 hours. After 24 hours, discard the culture medium, rinse twice with PBS, add 100u of DMEM culture medium containing 10% CCK-8 to each well, culture in a cell culture incubator, and measure the absorbance at 450nm.

[0102] Survival rate (%) = absorbance of test well / absorbance of normal group × 100%

[0103] Protective effect of lotus leaf crude polysaccharide on LPS-induced inflammation model

[0104] Culture RAW264.7 mouse macrophages and collect them after they grow normally to the logarithmic growth phase. Resuspend the cells in complete medium containing serum and adjust the cell density to 1x10 5 , then use a spray gun to add 100μL of cell suspension to each well, evenly spread it on the inside of the 96-well plate, and seal it with an equal amount of PBS around it. Culture in the incubator for 12 hours, and subsequent experiments can be carried out after the cells adhere to the wall. Then discard the supernatant in the 96-well plate, add 100μL of the prepared lotus leaf crude polysaccharide solution of different concentrations to the well plate according to 100μL per well, and incubate for 24 hours. Discard the supernatant again, add 100μL of lotus leaf crude polysaccharide solution of different concentrations and 100μL of LPS solution to make the final concentration of 1μg / mL, and incubate together for 24 hours. Collect the supernatant and cells for subsequent experiments.

[0105] Inflammatory factors

[0106] The contents of TNF-α, IL-6, IL-1β, IL-10 and NO in the supernatant were determined by ELISA.

[0107] Antioxidant index

[0108] The supernatant and cell homogenate were taken to determine the contents of SOD, LDH, GSH and CAT respectively.

[0109] Anti-inflammatory effect of crude lotus leaf polysaccharide on DSS-induced enteritis in mice

[0110] Male C57BL / 6 mice aged 6-8 weeks, weighing 18-20g, and free of specific pathogens (SPF) were randomly divided into control group (n=10), DSS group (n=10), and DSS+lotus leaf crude polysaccharide high, medium and low dose (50mg / kg 100mg / kg 200mg / kg) group (n=10). The ordinary drinking water of the DSS group and DSS+lotus leaf crude polysaccharide group was replaced with 2% (w / v) DSS drinking water. For 7 days to induce enteritis, mice in the DSS+lotus leaf crude polysaccharide group were gavaged with lotus leaf crude polysaccharide high, medium and low dose (50mg / kg 100mg / kg 200mg / kg) from day 1 to day 7. The mice in the control group and the DSS group were gavaged with the same amount of distilled water at the same time. During the experiment, the weight, stool hardness and rectal bleeding of the mice were recorded daily.

[0111] Disease Activity Index

[0112] The disease activity index includes 3 indicators: weight loss (0-4, 0 to 20% reduction), stool consistency (0 points for normal, 2 points for loose stools, and 4 points for diarrhea), and fecal occult blood (0 points for normal, 2 points for positive occult blood, and 4 points for obvious bleeding).

[0113] Histological analysis of mouse colon

[0114] The distal colon (about 3.5 cm from the anus) was washed with ice-cold phosphate buffered saline (PBS) and the colon length was measured. The 3 cm ileum and colon tissue near the ileum were fixed in 4% paraformaldehyde, dehydrated in ethanol, and embedded in paraffin, followed by PAS and eosin (H&E) staining. The morphology of the colon was observed using an optical microscope.

[0115] Intestinal barrier: Colon sections were stained using immunofluorescence and changes in TJ proteins were analyzed under a fluorescence microscope.

[0116] Analysis of inflammation parameters

[0117] Blood samples collected from each mouse were centrifuged at 4000 g for 10 min at 4°C to collect serum. The concentrations of NO, tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-1β, and IL-10 factors in serum and colon homogenate were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

[0118] Gut microbiota analysis

[0119] Using FastDNA TM Spin Kit for Feces (MPBiomedicals, Santa Ana, CA) was used to extract DNA according to its manual. The purity and quality of genomic DNA were checked in 0.8% agarose gel. The V3-V4 hypervariable region of the 16Sr RNA gene was amplified using primers 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTWTCTAAT) and then sequenced using the Illumina NovaSeq 6000 system. The raw data were screened to exclude sequences shorter than 200 bp, sequences with low quality scores (≤20), sequences containing ambiguous bases, or sequences that did not fully match the primer sequence and barcode tag from consideration. Qualified sequences were separated using sample-specific barcode sequences and trimmed using the Illumina sequencing analysis pipeline version 2.6. Afterwards, the dataset was analyzed using QIIME. These sequences were clustered into operational taxonomic units (OTUs) with a similarity of 97%. The taxonomic assignment of operational taxonomic units (OTUs) to represent sequences was determined by the GreenGenes database (version 13.8). Bayes was performed with a confidence threshold of 0.8.

[0120] Protective effect of lotus leaf crude polysaccharide on salpingitis in laying hens

[0121] 24 healthy Hailan brown laying hens were randomly divided into 4 groups, 6 in each group, including lotus leaf polysaccharide group, western medicine control group, model control group and blank control group. After 7 days of adaptive feeding, the lotus leaf polysaccharide group was given 20 mg / kg by gavage every morning and evening, the western medicine control group was given the dosage of amoxicillin according to the instructions, with a dose of 0.25 g / kg, and the blank control group and model control group were gavaged with the same volume of normal saline. On the 14th day of the experiment, except for the blank control group, the remaining groups were injected with mixed bacterial solution (Escherichia coli and Staphylococcus aureus 1:2) 2 ml / hen through the oviduct orifice, and the bacteria were given continuously for 7 days.

[0122] During the experiment, the number of eggs laid by laying hens was counted every day, including broken eggs, shaved eggs, shellless eggs and damaged eggs. After the experiment, blood was collected from the wing vein to detect the number of white blood cells; fresh oviduct tissue samples were collected to prepare tissue sections, HE staining, and observe pathological changes in oviduct tissue.

[0123] Experimental Results

[0124] 1. In the preparation of crude lotus leaf polysaccharide, 11.9303 g of polysaccharide was extracted from 350 g of lotus leaf, with a yield of 3.408%.

[0125] 2. In vitro antioxidant capacity of lotus leaf crude polysaccharides: Figure 1 As can be seen, with the increase of the concentration of lotus leaf crude polysaccharides, its DPPH scavenging ability and total antioxidant capacity increased. Figure 1 As shown in B, when the crude lotus leaf polysaccharide is above 4 mg / mL, the ABTS capacity no longer increases and reaches a constant value, indicating that the crude lotus leaf polysaccharide has antioxidant capacity.

[0126] 3. Safe concentration of lotus leaf crude polysaccharide: Figure 2 It can be seen that when the crude lotus leaf polysaccharide was equal to or greater than 400ug / mL, the crude lotus leaf polysaccharide inhibited the activity of RAW264.7 cells, so we took 200ug / mL as the safe concentration of crude lotus leaf polysaccharide.

[0127] 4. Lotus leaf crude polysaccharide improves the release of inflammatory factors caused by LPS: Figure 3 As shown, crude lotus leaf polysaccharides inhibited the release of NO, TNF-α, IL-6, IL-1β, and IL-10, and the effect increased with the increase of the concentration of crude lotus leaf polysaccharides.

[0128] 5. Lotus leaf crude polysaccharide improved the indicators related to oxidative stress caused by LPS: Figure 4 As shown, lotus leaf crude polysaccharide enhanced the SOD and GSH activities induced by LPS, reduced the LDH and CAT activities, and the effect increased with the increase of lotus leaf crude polysaccharide concentration.

[0129] 6. Lotus leaf crude polysaccharide improves DSS-induced enteritis: The protective effect of lotus leaf crude polysaccharide on mice was evaluated by body weight, DAI, colon length and histological examination of distal colon. Figure 5 As shown in Figure 2, DSS administration caused the body weight of mice in the administration group to decrease on the third day. Although the mice in the LLP group also lost weight, the decrease was significantly less than that in the DSS group. Figure 5 As shown in B, the DAI scores of mice in the DSS group increased significantly, while the scores of mice in the Con group dynamically approached 0 throughout the experiment. Importantly, the intervention of LLP significantly reduced the DAI score compared with the DSS group. The colon length of mice in the DSS group was reduced, while LLP treatment reversed the DSS-induced colon shortening ( Figure 5 C). Histological examination of the distal colon in the DSS group showed severe mucosal inflammation, often accompanied by crypt damage, infiltration, ulceration, and edema of the intestinal epithelial layer. These pathological changes in the colon of the LLP group were alleviated ( Figure 6 A). PAS staining of colon sections. Figure 6 B shows that the number of goblet cells in the DSS group was significantly reduced, and the lotus leaf crude polysaccharide can significantly increase the number of goblet cells in the colon tissue, indicating that the lotus leaf crude polysaccharide protects the intestinal function. In addition, we also found that the thymus of mice stimulated by DSS was atrophied and the spleen was swollen. The spleen index of mice treated with LLP was reduced compared with that of the DSS group, and the thymus index of mice treated with LLP was increased compared with that of the DSS group ( Figure 7 ).

[0130] 7. Lotus leaf crude polysaccharide can improve intestinal barrier damage caused by DSS: DSS-induced enteritis can damage the intestinal barrier. We selected three common TJ proteins for staining, such as Figure 8 As shown, we can find that lotus leaf crude polysaccharide can significantly increase the content of TJ protein (ZO-1, Occludin, Claudin-1), thereby protecting the intestinal barrier and improving enteritis.

[0131] 8. Lotus leaf crude polysaccharides can reduce the inflammation level of UC mice. Fig. 9 , 10 The effects of LLP on systemic indices of colonic mucosal inflammation in DSS-induced UC mice were shown. The concentrations of proinflammatory cytokines TNF-α, IL-6, IL-1β, and NO in the serum and colon homogenates of mice in the DSS group were significantly increased, while the concentration of IL-10 was decreased, but there was a significant difference between the LLP group and the DSS group.

[0132] 9. Effect of LLP on the intestinal microbiota of DSS-induced UC mice: The intestinal microbiota of mice in the Con, DSS, and LLP groups were detected by high-throughput pyrosequencing of the V3-V4 region of 16S rDNA. Fig.11 As shown in A, the α diversity of the microbial community in the DSS group decreased significantly in terms of microbial evenness (Pielou-e index) and microbial diversity (Shannon index). Compared with the DSS group, the LLP-H group increased the microbial richness of the microbial community and decreased the microbial evenness, but there was no significant difference in microbial diversity between the two groups. The samples were subjected to β diversity analysis, as shown in Fig.11 .B It can be seen that there are significant differences between the experimental groups and the control group, which indicates that drinking DSS water has a great impact on the intestinal flora of mice. There are also different differences among the LLP groups, but they are completely separated from the DSS group, indicating that LLP has a certain effect on the intestinal flora of mice after drinking DSS water. Venn diagram is used to show the overlap of OTUs in fecal microbiota between groups ( Fig.11 C); The five groups shared 297 OTUs in the intestinal microbiota: the Con group and the DSS group shared 807 OTUs, the LLP-H and Con groups shared 651 OTUs, and the DSS and LLP-H groups shared 586 OTUs. PCA analysis based on OTU abundance showed that the points of the DSS group were scattered on the lower right side, indicating that the microbial structure of the DSS group had changed dramatically compared with the normal group. However, in the LLP group and the Con group, the points were clustered on the upper left side, indicating that LLP can promote the structural recovery of the intestinal microbiota. The microbial structure of the LLP group was more similar to that of the Con group ( Fig.11 D).

[0133] 10. Improvement of microbial flora by LLP: At the phylum level, compositional analysis showed that Firmicutes and Bacteroidetes dominated the intestinal microbiota of all groups of mice, although their relative abundances varied between groups ( Fig.12 A). Compared with the Con group, the relative abundance of Bacteroidetes increased in the DSS group, while the abundance of Firmicutes decreased. Compared with the DSS group, the abundance of Firmicutes increased in the LLP-H group, while the abundance of Bacteroidetes decreased. At the family level, component analysis showed that compared with the Con group, the relative abundance of S24-7 and Erysipelotrichaceae increased in the DSS group, while the abundance of Lachnospiraceae and Ruminococcaceae decreased, while compared with the DSS group, the abundance of Lachnospiraceae and Ruminococcaceae increased in the LLP-H group, while the abundance of S24-7 decreased ( Fig.12 .B). At the genus level, compared with the Con group, the abundance of Allobaculum, Oscillospira, and Odorribacter decreased, and the abundance of Bacteroides increased in the DSS group, while compared with the DSS group, the abundance of Allobaculum and Odorribacter increased, and the abundance of Bacteroides decreased in the LLP-H group ( Fig.12 C).

[0134] 11. Metabolic pathway analysis of microorganisms from the control, DSS, and LLP groups: To examine whether LLP affects the metabolic activity of the microbial communities in feces, we inferred their metagenomes using the PICRUSt algorithm and folded the genes into the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways at level 2 ( Fig.13 ). Fig.13 The biosynthetic pathways were expected to be enriched compared to other pathways. These results suggest that LLP may restore colonic mucosal damage by increasing amino acid biosynthesis and nucleotide biosynthesis pathways.

[0135] We examined the changes in the content of intestinal barrier proteins, intestinal mucosa, inflammatory cytokine content, and intestinal flora during LLP treatment. We found that in mice with DSS-induced mucosal barrier disruption, administration of LLP significantly altered intestinal mucosal morphology, restored intestinal function, reduced the content of inflammatory cytokines, and improved intestinal flora structure. Therefore, lotus leaf crude polysaccharides can improve the symptoms of ulcerative colitis.

[0136] 12. Effect of LLP on the number of eggs laid by each group of laying hens: Before bacterial challenge, there was no significant difference in the average daily egg production of laying hens in each group. After bacterial challenge, the egg production of the model group was significantly different from that before bacterial administration, indicating that the establishment of the salpingitis model by administration of 2 ml of mixed bacterial solution (Escherichia coli and Staphylococcus aureus 1:2) was successful. Compared with the model control group, the number of eggs laid by other drug groups after bacterial administration was significantly increased, especially the number of eggs laid by the lotus leaf polysaccharide group and the western medicine control group.

[0137] Table 1 Statistical results of the number of eggs laid by each group (unit: egg)

[0138]

[0139] 13. Effect of LLP on oviduct inflammation in laying hens Results: The chickens in each group were autopsied and the results were shown in Fig.14 As can be seen from the figure, the oviducts of the blank group were normal, with no visible abnormalities. Compared with the blank group, yolk rupture was observed in the abdominal cavity of the chickens in the model group, and there was a peculiar smell in the abdominal cavity. No obvious inflammatory changes were observed in the oviducts of the chickens in the lotus leaf polysaccharide group and the western medicine control group.

[0140] 14. Effect of LLP on the number of white blood cells in laying hens with salpingitis: The number of white blood cells, neutrophils and eosinophils in each test group was significantly lower than that in the model group (P<0.05), and the number of white blood cells and neutrophils was not significantly different from the blank group (P>0.05). The number of eosinophils in the lotus leaf polysaccharide group was significantly higher than that in the blank control group (P<0.05), but was not significantly different from the western medicine control group. The above results show that lotus leaf polysaccharide has a certain alleviating effect on bacterial-induced salpingitis in laying hens.

[0141] 15. Effect of LLP on the morphology of oviduct tissue in laying hens: The oviduct structure of the blank group was intact, without inflammatory cell infiltration, and the tissues were tightly connected. In the model group, a large number of inflammatory cell infiltrations, cell death, vacuolation and dispersion, and more adhesion to the lumen were observed. The oviduct wall of the lotus leaf polysaccharide group was completely connected, with some tissues scattered and unclear stratification. The oviduct wall of the western medicine control group was intact, with divergent tissues and a small amount of cell vacuolation.

[0142] It should be noted that the above examples are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention is described in detail with reference to the given examples, those skilled in the art may modify or replace the technical solution of the present invention as needed without departing from the spirit and scope of the technical solution of the present invention.

Claims

1. Application of lotus leaf crude polysaccharide in any one or more of the following; (a) Anti-oxidation or preparation of anti-oxidation products; (b) Anti-inflammatory or preparation of anti-inflammatory products; (c) regulating intestinal flora disorders or preparing products for regulating intestinal flora disorders.

2. The use according to claim 1, characterized in that: In the above (a), the antioxidant capacity is specifically manifested as the improvement and / or enhancement of DPPH scavenging rate, ABTS scavenging capacity and total antioxidant capacity of T-AOC.

3. The use according to claim 1, characterized in that: In said (b), said anti-inflammatory activity is specifically manifested as in vitro anti-inflammatory activity and in vivo anti-inflammatory activity; The in vitro anti-inflammatory ability is manifested in that lotus leaf polysaccharide improves LPS-mediated oxidative stress response and inflammatory factor release; Lotus leaf crude polysaccharide enhanced the activity of SOD and GSH induced by LPS, reduced the activity of LDH and CAT, and inhibited the release of inflammatory factors such as NO, TNF-α, IL-6, IL-1β, and IL-10. The anti-inflammatory ability in vivo is specifically manifested in the prevention and / or treatment of inflammatory diseases; Wherein, the inflammatory diseases at least include ulcerative enteritis and salpingitis; Prevention and / or treatment of ulcerative enteritis at least includes: reduction in weight loss of subjects, reduction in DAI score, restoration of intestinal mucosal damage, reduction in inflammatory cell infiltration, and reduction in inflammation level; Prevention and / or treatment of fallopian tube inflammation at least includes: increasing egg production, relieving fallopian tube inflammation symptoms, and restoring the physiological function of the fallopian tube.

4. The use according to claim 1, characterized in that: In the above (c), regulating the intestinal flora disorder is specifically manifested as: reversing the intestinal microbial flora disorder caused by DSS, specifically at least increasing the abundance of Firmicutes and reducing the abundance of Bacteroidetes.

5. The use according to claim 1, characterized in that: The user of the product is a human or non-human animal, wherein the non-human animal is a mammal or a bird, further comprising livestock and poultry, and mammals and birds kept as pets; The product is a drug or a food. When the product is administered to non-human animals, the drug is a veterinary drug, and the food is a feed additive (or a pet food additive).

6. A method for preparing crude lotus leaf polysaccharide, characterized in that: The preparation method comprises: (1) extracting lotus leaves through alcohol to remove fat-soluble small molecules and pigments, thereby obtaining lotus leaf residues; (2) drying the lotus leaf residue obtained in step (1), adding water and heating it for extraction, filtering it and collecting the filtrate; (3) subjecting the filtrate obtained in step (2) to alcohol precipitation and collecting the precipitate; (4) After removing the protein from the precipitate in step (3), crude lotus leaf polysaccharide is obtained.

7. The preparation method according to claim 6, characterized in that: In the step (1), the specific method of alcohol extraction includes: using high concentration ethanol at 70-90° C. under reduced pressure reflux for 2-4 times, each time for 1-3 hours; In the step (2), the drying is natural drying in the shade, and the specific conditions for water-adding heating extraction include: the extraction temperature is controlled at 90-100° C., the extraction time is 1-3 hours, and the number of extractions is 1-3 times.

8. The preparation method according to claim 6, characterized in that: In the step (3), the alcohol precipitation treatment method comprises: adding 90% ethanol to the filtrate to make the final concentration 80%, precipitating the polysaccharide with alcohol, and collecting the precipitate after standing; the standing treatment time is 10-40 hours; In the step (4), the protein is removed by the Sevage method; further, the solution obtained after the protein is removed is dialysis bag with 3.5KDa in flowing water for 48 hours to remove organic reagents to obtain a crude polysaccharide solution; the crude polysaccharide solution is freeze-dried to obtain lotus leaf crude polysaccharide.

9. A product, characterized in that The product at least comprises the crude lotus leaf polysaccharide obtained by the preparation method according to any one of claims 6 to 8.

10. The product according to claim 9, characterized in that The product is a drug or a food. When the product is administered to a non-human animal, the drug is a veterinary drug, and the food is a feed additive (or a pet food additive). The product has any one or more of the following uses: (a) Antioxidant; (b) anti-inflammatory; (c) Regulate intestinal flora disorders.

Citation Information

Cited By

  • Lotus leaf homogeneous polysaccharide LLP3-1 as well as separation and purification method and application thereof

    CN121343018A